FFO
ERNA icon

Fortitude Family Office’s Eterna Therapeutics ERNA Stock Holding History

Fortitude Family Office’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32
Closed -$965 – 1948
2025
Q4 		$965 Buy
+32
New +$1.09K ﹤0.01% 1470

Other funds holding ERNA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Fortitude Family Office's ERNA Position: Q1 2026 in Review

Fortitude Family Office sold out of Eterna Therapeutics (ERNA) in Q1 2026, closing a stake of 32 shares — an estimated $965 sold.

Fortitude Family Office first reported a position in ERNA in Q4 2025 and held it in 1 quarter. The position peaked at $965 in Q4 2025. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

  • Fortitude Family Office reported no remaining Eterna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 32 Eterna Therapeutics shares in Q1 2026, an estimated $965.
  • Fortitude Family Office first reported a position in Eterna Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fortitude Family Office's Eterna Therapeutics position peaked at $965 in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.